A move to cover expensive weight-loss drugs for Americans on Medicare and Medicaid may be in the works, but any such program could run into problems with voluntary participation and concerns about expense.

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity medications.

Medicare and Medicaid could expand coverage of GLP-1 drugs, such as Ozempic and Wegovy, and pay for patients’ use of the weight loss drugs, according to a new report.